Investor Presentaiton

Company overview Financial review 2022 priorities Appendix References Broad pipeline of novel medicines continued to progress in Q2 Hematology Solid tumors Immunology Neuroscience Cardiovascular Approvals TabrectaⓇ TafinlarⓇ+ MekinistⓇ JakaviⓇ KymriahⓇ EU: adv. non-small cell lung cancer US: tumor-agnostic for BRAF V600E solid tumors EU: acute and chronic GVHD Readouts and publications icenticaftor sabatolimab Ph2 - COPD¹ CosentyxⓇ Ph2-HR-MDS STIMULUS MDS-1 Ph3-axSpA IV INVIGORATE US and EU: r/r follicular lymphoma Cosentyx® Submissions Ph2 lichen planus PRELUDE³ BeovuⓇ CosentyxⓇ US and JP: diabetic macular edema EU: JPSA & ERA CosentyxⓇ adalimumab EU: hidradenitis suppurativa EU 3 INNOVATION 2 Designations and milestones ScemblixⓇ pelacarsen JDQ443 EU positive CHMP for CML 3L Ph3 HORIZON recruitment completed Ph3 2/3L NSCLC initiated Selected milestones 1. Ph2b DRF demonstrated dose response across multiple endpoints, study results presentation end 2022 Biosimilar Exiting development projects: COPD, general asthma CSJ117 icenticaftor Decision to partner Decision to partner 2. Submission will be based on Ph3 results 3. Data analysis on-going 17 Investor Relations | Q2 2022 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation